STUDY SEARCH RESULTS

1 study found for your search request:  1026-010

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relaps...
Condition: Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic, CLL, SLL
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT05947851
Status: Recruiting
Has Enrolling Locations in US or Canada




Copyright © 2026 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  Consumer Health Data Privacy Policy  Your Privacy Choices   Accessibility  U.S. Corporate Site